Hourmant M, Soulillou J P
Service de Néphrologie et Immunologie Clinique, C. H. R., Nantes.
Biomed Pharmacother. 1987;41(5):247-9.
In this randomized one-center study in kidney transplantation delayed administration of CyA following conventional treatment with anti-thymocyte globulin (ATG) (group CyA, 48 patients) is compared with conventional treatment (including ATG) as sole immuno-suppressive treatment (group STD, 27 patients). Graft survival was significantly better with CyA (84% vs. 63% at 3 years). CyA efficacy seemed related with the decrease of rejection severity rather than of its frequency. Delayed introduction of the drug reduced its nephrotoxicity and short and longterm transplant function of patients under CyA were similar to controls. Finally from the 1st year post-grafting corticosteroids were withdrawn in more than 80% of recipients receiving CyA.
在这项单中心随机肾脏移植研究中，将抗胸腺细胞球蛋白（ATG）常规治疗后延迟给予环孢素A（CyA组，48例患者）与作为唯一免疫抑制治疗的常规治疗（包括ATG）（STD组，27例患者）进行比较。CyA组的移植物存活率显著更高（3年时分别为84%和63%）。CyA的疗效似乎与排斥反应严重程度的降低有关，而非其发生频率。延迟引入该药物降低了其肾毒性，接受CyA治疗患者的短期和长期移植功能与对照组相似。最后，在移植后第1年，超过80%接受CyA治疗的受者停用了皮质类固醇。
